Phase I (2000-06)

in page functions

Gavi's first five-years focused on getting funds to countries quickly to extend the reach and quality of immunisation programmes

In Gavi's first six years, the Vaccine Alliance concentrated on two primary areas:

  1. supply of new and underused vaccines;
  2. strengthening vaccine delivery systems.

From 2000-06, Gavi's new and underused vaccine support (NVS) focused on three underused vaccines: hepatitis B (hepB), Haemophilus influenzae type b (Hib) and yellow fever.
 

Support was provided in the form of five-year grants with the expectation that countries would increase their national contribution, leading to eventual financial sustainability.

Delivery systems were improved through Gavi's injection safety support (INS) initiatives. As most infections result from the re-use of equipment, Gavi enabled the supply of disposable auto-disable (AD) syringes for all vaccines to all countries. In addition to minimising infection risk, this helped to drive down the price of AD syringes and increased vaccine demand.

Incentives to immunise more children were given through performance-based funding known as immunisation services support (ISS) with countries receiving extra money per additional child immunised.

Gavi catalyses new injection safety standards

In Gavi’s first 10 years, 58 countries successfully applied for injection safety support. All but two continued to use auto-disposable syringes even after Gavi's support stopped.


 

Learn more... 

Uganda INS 2009 AD syringes box

Every 2 minutes

One woman dies from cervical cancer every two minutes – or 266,000 a year – over 85% in the developing world. If current trends hold, and without changes in prevention and control, cervical cancer deaths could eventually outpace maternal deaths. HPV vaccines can prevent up to 90% of all cervical cancer cases.

WHO

More facts...

close icon

modal window here